Takamochi Kazuya, Suzuki Kazuya, Sugimura Haruhiko, Funai Kazuhito, Mori Hiroki, Bashar Abul Hasan Muhammad, Kazui Teruhisa
First Department of Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 435-3192, Japan.
Lung Cancer. 2007 Oct;58(1):149-55. doi: 10.1016/j.lungcan.2007.04.016. Epub 2007 Jun 4.
Gefitinib is the first approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who failed to respond to conventional chemotherapy. Gefitinib has fairly effective anti-tumour activity in patients with tumours harboring EGFR gene mutations. However, there has been no data about the preoperative gefitinib treatment in NSCLC patients. We reported here two cases of surgical resection of residual disease after dramatic response to gefitinib in patients with lung adenocarcinoma harboring EGFR gene mutation. Because both of our patients initially had advanced local tumour burden (bulky N2 disease), complete resection would not have been technically feasible. However, preoperative gefitinib treatment made it possible to achieve complete resection in both patients. We believe that clinical trials are required to evaluate the role of preoperative treatment of EGFR-TKIs in patients with locally advanced NSCLC harboring EGFR gene mutation.
吉非替尼是首个被批准用于治疗对传统化疗无反应的晚期非小细胞肺癌（NSCLC）患者的表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）。吉非替尼对携带EGFR基因突变的肿瘤患者具有相当有效的抗肿瘤活性。然而，目前尚无关于NSCLC患者术前使用吉非替尼治疗的数据。我们在此报告了2例携带EGFR基因突变的肺腺癌患者在对吉非替尼产生显著反应后进行手术切除残留病灶的病例。由于我们的两名患者最初都有晚期局部肿瘤负荷（巨大N2期疾病），从技术上来说完全切除是不可行的。然而，术前吉非替尼治疗使两名患者都有可能实现完全切除。我们认为需要进行临床试验来评估术前使用EGFR-TKIs治疗对携带EGFR基因突变的局部晚期NSCLC患者的作用。
